“3 Years of Tralokinumab Treatment Provides Long Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Modera Te to Severe Atopic Dermatitis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s142. https://doi.org/10.25251/skin.7.supp.142.